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Aim: To compare alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, with
usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not opti-
mally managed by maximally tolerated statins in the ODYSSEY DM-DYSLIPIDEMIA trial
(NCT02642159).
Materials and Methods: The UC options (no additional lipid-lowering therapy; fenofibrate; eze-
timibe; omega-3 fatty acid; nicotinic acid) were selected prior to stratified randomization to
open-label alirocumab 75 mg every 2 weeks (with increase to 150 mg every 2 weeks at week
12 if week 8 non-HDL cholesterol concentration was ≥2.59 mmol/L [100 mg/dL]) or UC for
24 weeks. The primary efficacy endpoint was percentage change in non-HDL cholesterol from
baseline to week 24.
Results: The randomized population comprised 413 individuals (intention-to-treat population,
n = 409; safety population, n = 412). At week 24, the mean non-HDL cholesterol reductions
were superior with alirocumab (−32.5% difference vs UC, 97.5% confidence interval −38.1 to
−27.0; P < .0001). Overall, 63.6% of alirocumab-treated individuals were maintained on 75 mg
every 2 weeks. Alirocumab also reduced LDL cholesterol (−43.0%), apolipoprotein B (−32.3%),
total cholesterol (−24.6%) and LDL particle number (−37.8%) at week 24 vs UC (all P < .0001).
Consistent with the overall trial comparison, alirocumab reduced non-HDL cholesterol to a
greater degree within each UC stratum at week 24. The incidence of treatment-emergent
adverse events was 68.4% (alirocumab) and 66.4% (UC). No clinically meaningful effect on gly-
cated haemoglobin, or change in number of glucose-lowering agents, was seen.
Conclusions: In individuals with T2DM and mixed dyslipidaemia on maximally tolerated statin,
alirocumab showed superiority to UC in non-HDL cholesterol reduction and was generally well
tolerated.
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1 | INTRODUCTION
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of
morbidity and mortality among individuals with type 2 diabetes melli-
tus (T2DM).1 The reasons are probably multifactorial, but a relevant
contributory factor may be the greater prevalence of mixed dyslipi-
daemia, which is characterized by elevated triglyceride (TG) levels and
thus elevated TG-rich lipoprotein (TRL) and TRL cholesterol levels, as
well as low levels of HDL cholesterol.2 Mixed dyslipidaemia in T2DM
might not be detected with measurement of LDL cholesterol levels, as
these may remain within a normal range.3 Non-HDL cholesterol (cal-
culated by subtracting HDL cholesterol from total cholesterol),
accounts for the sum of all atherogenic lipoproteins (LDL cholesterol,
intermediate-density lipoprotein, very-low-density lipoprotein [VLDL],
VLDL remnants, chylomicron remnants, and lipoprotein a [Lp(a)]) and
has been suggested to be a better indicator of cardiovascular
(CV) risk than LDL cholesterol among individuals with elevated TG
levels, including individuals with dyslipidaemia.3–5 Populations with
mixed dyslipidaemia also have qualitative changes in LDL particles,
with a higher number of smaller, more dense LDL particles; these are
believed to be more atherogenic than larger, more buoyant
particles.2
Lipid-lowering therapy (LLT) with statins increases the clearance
of atherogenic lipoproteins and thus reduces plasma cholesterol
levels, principally through reductions in LDL cholesterol.6 This results
in a significantly lower risk of ASCVD with the proportional benefit
related to the absolute reduction in LDL cholesterol.7 Other thera-
peutic approaches that further increase clearance of atherogenic lipo-
proteins include ezetimibe8 and the inhibitors of proprotein
convertase subtilisin-kexin type 9 (PCSK9), alirocumab9 and evolocu-
mab.10 Adding ezetimibe or evolocumab to statin significantly
reduces CV events (the CV outcomes study with alirocumab
[NCT01663402] is ongoing)11,12; however, no previous study has
prospectively evaluated PCSK9 inhibition in individuals with diabe-
tes and mixed dyslipidaemia or compared different therapeutic
options among individuals with elevated TG levels despite maximally
tolerated statin therapy, an important consideration given the “real-
world” clinical uncertainty around potential therapeutic agents
which principally reduce either the synthesis of TRL particles
(fibrates), lipolysis of TGs (omega-3 fatty acids), clearance of athero-
genic lipoproteins (ezetimibe), or a combination of these mecha-
nisms (nicotinic acid).
The ODYSSEY DM-DYSLIPIDEMIA trial was designed to address
these clinical uncertainties and assessed the efficacy and safety of
alirocumab vs usual lipid-lowering care (UC), stratified by an investi-
gator's predefined option for add-on therapy (fenofibrate, omega-3
fatty acids, ezetimibe, nicotinic acid or no additional LLT) to
maximally tolerated statins among individuals with T2DM at high
ASCVD risk who had mixed dyslipidaemia and in whom non-HDL
cholesterol was not adequately controlled (≥2.59 mmol/L [≥100 mg/
dL]). The primary endpoint (not used in previous randomized studies)
was the difference in the percentage change from baseline in non-
HDL cholesterol between alirocumab and UC (overall; ie, all options).
A prespecified analysis was used to compare the superiority of aliro-
cumab vs fenofibrate (recommended in guidelines for treating individ-
uals with elevated TGs4,5).
2 | MATERIALS AND METHODS
2.1 | Study design
ODYSSEY DM-DYSLIPIDEMIA (NCT02642159) was a phase IIIb/IV,
randomized, open-label, parallel group, multicentre trial. The trial was
conducted at 110 sites in 14 countries; screening started in March
2016 and recruitment was completed in September 2016. The study
design and methods have been published previously.13 Brief methods
are summarized below and further details are provided in Appen-
dix S1.
The trial was conducted in accordance with the ethical principles
laid down by the 18th World Medical Assembly (Helsinki, 1964) and
all applicable amendments laid down by the World Medical Assem-
blies, and the International Conference on Harmonisation guidelines.
The trial protocol was approved by the relevant institutional review
boards or independent ethics committees, and all participating indi-
viduals provided written informed consent.
2.2 | Trial participants
The trial included individuals (aged ≥18 years) with T2DM and mixed
dyslipidaemia whose non-HDL cholesterol was not adequately controlled
despite stable maximally tolerated statin dose for ≥4 weeks prior to
screening visit, without other LLTs, and who had either a documented
history of ASCVD or at least 1 additional CV risk factor. Study
participants had to have a glycated haemoglobin (HbA1c) of <9% (74.9
mmol/mol); changes to antihyperglycaemic medications were to be lim-
ited and made only in circumstances of clinical need for the duration of
the study.
Mixed dyslipidaemia was defined as non-HDL cholesterol
≥2.59 mmol/L (≥100 mg/dL) and TGs ≥1.70 mmol/L (150 mg/dL; but
<5.65 mmol/L [500 mg/dL]) at the screening visit. The maximally tol-
erated dose of statin was based on the judgment of the investigator.
Individuals with documented statin intolerance (as judged by the
investigator) and therefore not receiving statin therapy could also be
enrolled. ASCVD was defined as coronary heart disease, peripheral
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arterial disease or ischaemic stroke. Full inclusion and exclusion cri-
teria have been reported previously.13
2.3 | Study procedures
After a screening period of up to 3 weeks, investigators selected
before randomization the most appropriate choice from a range of
5 therapeutic options based on their usual clinical practice, namely,
not to add any LLT, or to add 1 of the following: ezetimibe, fenofi-
brate, omega-3 fatty acid formulation or nicotinic acid. Participants
were randomized in a 2:1 ratio to receive, on top of maximally toler-
ated statin (or no statin if intolerant), either open-label alirocumab or
UC for 24 weeks. Randomization was stratified by the UC option
selected by the investigator prior to randomization.
Alirocumab was initiated at a dose of 75 mg every 2 weeks, with
blinded dose increase to 150 mg every 2 weeks at week 12 if week
8 non-HDL cholesterol was ≥2.59 mmol/L (≥100 mg/dL), henceforth
referred to as “alirocumab 75/150 mg every 2 weeks.”
2.4 | Endpoints and assessments
The primary efficacy endpoint was the percentage change in non-
HDL cholesterol from baseline to week 24, analysed using an
intention-to-treat approach. Further details on secondary endpoints
and laboratory and safety assessments are given in Appendix S1.
2.5 | Statistical analysis
The primary efficacy endpoint was analysed using a mixed-effect model
with a repeated measures approach to account for missing data. Further
information on analysis methods is presented in Appendix S1.
3 | RESULTS
3.1 | Participating individuals
Eligible individuals were allocated to UC options by the investigator
prior to randomization, and were subsequently randomized within
each stratum to either alirocumab or UC option in a 2:1 ratio
(Figure 1). A total of 413 individuals were randomized to alirocumab
(n = 276) or UC (n = 137). The median daily doses of UC treatments
are given in Table S1.
Baseline characteristics and lipid variables were generally similar
regardless of treatment allocation (Tables 1 and S2). At baseline,
84.0% of individuals in the alirocumab group and 76.6% in the UC
group were receiving statin therapy (of these, 46.3% [alirocumab] and
36.2% [UC] were receiving high-intensity statin). Treatment groups
included 34.4% and 34.3% of individuals with a history of ASCVD
and 65.6% and 65.7% without ASCVD but with additional CV risk
factors in the alirocumab and UC groups, respectively (Table 1).
FIGURE 1 Disposition of individuals for the DM-DYSLIPIDEMIA study. Abbreviations: ALI, alirocumab; FA, fatty acids; ITT, intention-to-treat;
LLT, lipid-lowering therapy; Q2W, every 2 weeks. aThirty-nine individuals were intended for “no LLT” prior to randomization; however,
37 actually received “no LLT.” One individual intended for “no LLT” received fenofibrate and another received ezetimibe. In total, 4 individuals
were not included in the ITT analysis (no non-HDL cholesterol value available within 1 of the analysis windows up to week 24) and 1 individual
was not included in the safety analysis (individual did not wish to continue prior to treatment)
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TABLE 1 Baseline characteristics (randomized population)
Alirocumab
75/150 mg every
2 weeks
n = 276
UC
n = 137
Age, years 62.8 (9.3) 64.1 (8.8)
Men 147 (53.3) 69 (50.4)
Race
White 247 (89.5) 123 (89.8)
Black 16 (5.8) 6 (4.4)
Ethnicity: Hispanic/Latin 35 (12.7) 14 (10.2)
Body mass index, kg/m2 32.7 (5.4) 33.2 (4.9)
HbA1c, % [mmol/mol] 7.1 (0.8)
[53.5 (9.1)]
7.1 (0.9)
[54.5 (9.4)]
HbA1c
<7% (<53.0 mmol/mol) 134 (48.6) 57 (41.6)
≥7% to <8% (≥53.0
mmol/mol to <63.9
mmol/mol)
100 (36.2) 56 (40.9)
≥8% to <9 (≥63.9
mmol/mol to <74.9
mmol/mol)
42 (15.2) 24 (17.5)
FPG
mmol/L 8.04 (2.11) 8.22 (2.19)
mg/dL 144.9 (38.1) 148.1 (39.4)
Median (Q1:Q3) duration
of DM, years
10.7 (5.5:17.5) 11.5 (6.2:18.7)
Hypertensiona 241 (87.3) 123 (89.8)
Current cigarette smoker 38 (13.8) 23 (16.8)
CKDb 41 (14.9) 23 (16.8)
Individuals with ASCVD 95 (34.4) 47 (34.3)
Individuals without
ASCVD but with
additional CV risk
factor
181 (65.6) 90 (65.7)
Any statinc 231 (84.0) 105 (76.6)
High-intensity statind 107 (46.3) 38 (36.2)
Moderate-intensity
statind
103 (44.6) 64 (61.0)
Low-intensity statind 21 (9.1) 3 (2.9)
Any LLT other than
statinse before
randomization
1 (0.4) 2 (1.5)
Fenofibrates 1 (0.4) 1 (0.7)
Cholesterol absorption
inhibitor
0 1 (0.7)
Nutraceuticals
impacting lipids/
other
0 1 (0.7)
No LLTc (no statin or
other LLT)
44 (16.0) 32 (23.4)
Statin-intolerant 43 (15.6) 31 (22.6)
Concomitant
antihyperglycemic
drugsc
Biguanides 211 (76.7) 106 (77.4)
Insulin 102 (37.1) 56 (40.9)
Sulphonylureas 67 (24.4) 31 (22.6)
SGLT2 inhibitors 39 (14.2) 18 (13.1)
TABLE 1 (Continued)
Alirocumab
75/150 mg every
2 weeks
n = 276
UC
n = 137
DPP-4 inhibitors 36 (13.1) 20 (14.6)
GLP-1RA 32 (11.6) 21 (15.3)
Thiazolidinediones 9 (3.3) 5 (3.6)
α-glucosidase inhibitors 2 (0.7) 2 (1.5)
Other blood glucose-
lowering drugs
9 (3.3) 2 (1.5)
Baseline lipidsf
Non-HDL cholesterol
mmol/L 4.02 (1.20) 4.18 (1.26)
mg/dL 155.1 (46.2) 161.5 (48.8)
LDL cholesterol,
measuredg
mmol/L 2.86 (1.04) 3.04 (1.13)
mg/dL 110.4 (40.3) 117.3 (43.5)
ApoB, mg/dL [g/L] 101.9 (25.8)
[1.0 (0.3)]
106.1 (28.7)
[1.1 (0.3)]
Total cholesterol
mmol/L 5.06 (1.19) 5.25 (1.32)
mg/dL 195.4 (46.0) 202.5 (51.1)
Median (Q1:Q3) Lp(a),
mg/dL
16.0 (5.0:54.0) 15.0 (5.0:40.0)
Median (Q1:Q3) TGs
mmol/L 2.43 (1.91:3.22) 2.40 (1.90:3.12)
mg/dL 214.5 (169.0:285.0) 212.0
(168.0:276.0)
HDL cholesterol
mmol/L 1.04 (0.25) 1.06 (0.30)
mg/dL 40.3 (9.8) 41.1 (11.6)
LDL particle number,
nmol/L
1404.1 (456.1) 1483.8 (482.8)
ApoA1, mg/dL 138.6 (21.2) 139.4 (22.9)
LDL particle size, nm 20.3 (0.6) 20.3 (0.6)
Abbreviations: Alirocumab 75/150 mg Q2W, alirocumab 75 mg Q2W with
possible dose increase to 150 mg Q2W at Week 12; Apo, apolipoprotein;
ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney dis-
ease; CV, cardiovascular; DM, diabetes mellitus; DPP-4, dipeptidyl pepti-
dase 4; FPG, fasting plasma glucose; eGFR, estimated glomerular filtration
rate; GLP-1RA, glucagon-like peptide 1 receptor agonist; HbA1c, glycated
haemoglobin; LLT, lipid-lowering therapy; Lp(a), lipoprotein a; Q1/Q3, first/
third quartile; SGLT2, sodium-glucose co-transporter-2; TG, triglyceride;
UC, usual care. Data are mean (SD) or n (%), unless otherwise indicated.
a Established based on use of antihypertensive medication.
b Defined as eGFR 15–60 mL/min/1.73 m2.
c Data presented for safety population (275 alirocumab; 137 UC).
d High-intensity statin: atorvastatin 40 to 80 mg, rosuvastatin 20 to
40 mg or simvastatin 80 mg. Moderate-intensity statin: atorvastatin
10 to 20 mg, fluvastatin 40 mg, fluvastatin extended release 80 mg, lov-
astatin 40 mg, pitavastatin 2 to 4 mg, pravastatin 10 to 20 mg, rosuvas-
tatin 5 to 10 mg or simvastatin 20 to 40 mg. Low-intensity statin:
fluvastatin 20 to 40 mg, lovastatin 20 mg, pitavastatin 1 mg, pravastatin
10 to 20 mg or simvastatin 10 mg.
e In combination with statins or not.
f Order based on hierarchical order, except for LDL particle size.
g β-quantification.
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3.2 | Lipid variables
The least-squares mean (SE) percentage change from baseline to week
24 in non-HDL cholesterol was −37.3 (3.0)% with alirocumab and −4.7
(3.3)% with UC (−32.5% difference vs UC, 97.5% confidence interval
[CI] –38.1 to −27.0; P < .0001 [Figure 2A]). Alirocumab also significantly
lowered levels of measured LDL cholesterol, apolipoprotein (Apo)B, total
cholesterol and Lp(a) vs UC (all P < .0001; Figure 2A). Non-HDL choles-
terol and measured LDL cholesterol reductions were observed from the
first measured time point at week 8 and maintained through the 24-
week treatment period (Figure S1). TG levels were decreased in both
arms at week 24, with no significant difference between alirocumab
(−13.0%) vs UC (−8.8%; Figure 2A). As a result of the hierarchical testing
procedure used, P values from subsequent testing of secondary end-
points are nominal only. At week 24, alirocumab treatment resulted in
improvements from baseline (nominal P value <.025 vs UC) in HDL cho-
lesterol, and LDL particle number and size (Figure 2A). Results for
FIGURE 2 Primary and selected key secondary efficacy endpoints at week 24 for A, the overall study population; B, fenofibrate; C,
ezetimibe; D, omega-3 fatty acids and E, no lipid-lowering therapy (ITT analysis). Abbreviations: Apo, apolipoprotein; FA, fatty acids; HDL-C,
HDL cholesterol; ITT, intenttion-to-treat; LDL-C, LDL cholesterol; LDL-P, LDL particle; LLT, lipid-lowering therapy; Lp(a), lipoprotein (a); LS,
least-squares; TC, total cholesterol; TG, triglyceride. aStatistically significant according to the fixed hierarchical approach used to ensure a strong
control of the overall type I error rate at the 0.025 level. ITT analysis includes individuals according to planned treatment (see footnote to
Figure 1)
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fenofibrate stratum and other individual UC strata were similar to the
overall analysis (Figure 2B-E); as a result of small patient numbers, data
were not analysed for the nicotinic acid stratum. Similar results to those
at week 24 were seen at week 12, when all individuals in the alirocumab
arm were receiving the 75-mg dose (Figure S2). In the alirocumab group,
the dose of 75 mg every 2 weeks was maintained in 63.6% of individ-
uals after week 12.
At week 24, more than two-thirds of alirocumab-treated indi-
viduals achieved levels of non-HDL cholesterol <2.59 mmol/L
(<100 mg/dL), measured LDL cholesterol <1.81 mmol/L (<70 mg/dL)
and ApoB <80 mg/dL (<0.8 g/L; Figure 3). In addition, a greater
proportion of individuals in the alirocumab group vs UC achieved a
reduction in LDL cholesterol from baseline of ≥50% (55.2%
vs 3.8%).
Results were consistent across the various subgroups analysed
(Figure S3).
3.3 | Free and total PCSK9
In the alirocumab group, free PCSK9 levels changed by −43.3% and
−60.6% at week 12 and week 24, respectively (UC: +18.2% and
+11.8%, respectively; Figure 4). Total PCSK9 levels changed by
+357.6% at week 12 and +413.3% at week 24 in the alirocumab
group (UC: +13.9% and +10.8%, respectively; Figure 4). Correspond-
ing data within individual UC strata are also shown in Figure 4.
3.4 | Diabetes-related endpoints
The mean HbA1c and fasting plasma glucose (FPG) levels observed
during the study are shown in Figure S4. The mean (SE) absolute
change from baseline in HbA1c at week 24 was +2.58 (0.41) mmol/mol
in the alirocumab group and +2.10 (0.57) mmol/mol in the UC group
(P = .48); corresponding values in % for HbA1c were +0.24 (0.04)%
FIGURE 3 Proportion of individuals
achieving predefined lipid goals at A,
week 24 and B, week 12 (intention-to-
treat analysis; as-planned study cohorts).
Abbreviations: ALI, alirocumab; Apo,
apolipoprotein; FA, fatty acids; LDL-C,
LDL cholesterol; LLT, lipid-lowering
therapy; non-HDL-C, non-HDL
cholesterol; UC, usual care. *P < .05;
**P < .0001 vs control. Non-HDL
cholesterol: 2.6 mmol/L = 100 mg/dL;
LDL cholesterol: 1.8 mmol/L = 70 mg/dL;
ApoB: 0.8 g/L = 80 mg/dL
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(alirocumab group) and +0.19 (0.05)% (UC group). The mean
(SE) absolute change in FPG from baseline at week 24 was +0.32 (0.13)
and −0.01 (0.17) mmol/L in the alirocumab and UC groups, respectively
(P = .12 vs UC); corresponding values for FPG were +5.70 (2.25) and
−0.10 (3.07) mg/dL for alirocumab and UC, respectively. The median
total number of glucose-lowering treatments received remained stable
over time, with no change between baseline and week 24 (Table S3).
3.5 | Safety
The percentage of individuals who experienced any treatment-
emergent adverse events (TEAEs), treatment-emergent serious
adverse events and TEAEs leading to discontinuation was similar in
the alirocumab and UC groups (Table S4).
The TEAEs occurring in ≥2% of individuals were reported at gen-
erally similar frequencies in the alirocumab and UC groups, with some
TEAEs occurring at higher frequency in the alirocumab vs UC group
and vice versa; urinary tract infection (alirocumab: 5.8%; UC: 3.6%)
and diarrhoea (alirocumab: 5.1%; UC: 6.6%) were the most common
TEAEs (Table S5).
In total, 3.0% (n = 8) of individuals receiving alirocumab and 0.8%
(n = 1) of those receiving UC had low-titre persistent anti-drug anti-
bodies. At week 12, 0.7% (n = 2) of individuals in the alirocumab
group demonstrated positive neutralizing anti-drug antibodies; none
were observed at week 24. In the UC group, no neutralizing anti-drug
antibodies were observed.
4 | DISCUSSION
ODYSSEY DM-DYSLIPIDEMIA is the first dedicated study of a
PCSK9 inhibitor to evaluate efficacy and safety vs UC among individ-
uals with T2DM and mixed dyslipidaemia and elevated non-HDL cho-
lesterol levels despite maximally tolerated statin therapy, and the first
randomized trial to use non-HDL cholesterol as the primary endpoint.
The pragmatic design of this study with the choice of UC (in addition
to maximally tolerated statin therapy) based on the investigator's pre-
defined option allows, for the first time, a direct comparison with
multiple therapeutic alternatives to alirocumab and their effects on
non-HDL cholesterol as well as a range of lipoprotein markers
believed to be causally related to ASCVD.
FIGURE 4 Percent change from
baseline to A, week 12 and B, week
24 in levels of free and total PCSK9 in
individuals receiving alirocumab vs usual
care (PCSK9 analysis). Abbreviations:
ALI, alirocumab; FA, fatty acids; LLT,
lipid-lowering therapy; LS, least squares;
PCSK9, proprotein convertase subtilisin-
kexin type 9; UC, usual care
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Alirocumab demonstrated superiority from baseline to week
24 in reducing non-HDL cholesterol (by 32.5%), ApoB (32.3%),
Lp(a) (27.4%), total cholesterol (24.6%) and measured LDL cholesterol
(43.0%) vs UC. Alirocumab was not superior to UC in reducing TGs
and, because of the hierarchical nature of testing, the significant
increase in HDL cholesterol levels (+6.2%) and significant reductions
in LDL particle number (−37.8%) and LDL particle size (−1.8%) relative
to UC should be considered nominal. Moreover, in the present study,
66.9% of alirocumab-treated individuals achieved non-HDL choles-
terol levels <2.59 mmol/L (100 mg/dL; 17.7% with UC) and 70.8%
achieved LDL cholesterol levels <1.81 mmol/L (70 mg/dL) vs 16.3%
with UC.
Alirocumab was also superior to fenofibrate in reducing non-HDL
cholesterol (33.3% vs fenofibrate), ApoB (35.2%), Lp(a) (22.8%), total
cholesterol (25.3%) and measured LDL cholesterol (55.7%). At
week 24, the percentage change from baseline in the fenofibrate
group was equivalent to the alirocumab group in lowering TG and
raising HDL cholesterol when added to maximally tolerated statin
therapy. However, participants in the present study had moderately
elevated TG levels (median baseline TGs of ~2.4 mmol/L [~210 mg/
dL]), and conclusions cannot be extrapolated to those with more
severely elevated TG levels (>5 mmol/L), who were excluded from
the study. Nominally greater reductions from baseline to week 24 in
LDL particle number (42.4%) and LDL particle size (3.1%) favoured
alirocumab over fenofibrate. Furthermore, at week 24, 65.2% of
patients achieved non-HDL cholesterol levels <2.59 mmol/L
(<100 mg/dL) and 71.9% LDL cholesterol levels <1.81 mmol/L
(<70 mg/dL) with alirocumab vs 10.1% and 17.5%, respectively, with
fenofibrate. Directionally concordant results were observed favouring
alirocumab vs no LLT, omega-3 fatty acids or ezetimibe where sample
size allowed such comparisons.
The present study also offers novel insights into the potential
mechanisms behind changes in different lipid variables when other
LLTs are added to statins and the potential impact of these differen-
tial changes on the putative likelihood of future ASCVD. In the over-
all UC group, mean total and free PCSK9 concentrations changed by
+10.8% and +11.8%, respectively, at week 24 compared with base-
line; larger increases were seen in the fenofibrate group and also
(to a lesser extent) in the ezetimibe group, in line with previous
observations that treatment with these LLTs increases PCSK9
levels.14,15 Omega-3 fatty acids appeared to have a negligible effect
on PCSK9 levels. The increases in PCSK9 levels in the overall UC
group were associated with only modest reductions from baseline to
week 24 in ApoB (−1.6%) and LDL particle number (−3.9%), and
increase in LDL particle size (+0.3%) and therefore modest reductions
in non-HDL cholesterol (−4.7%) and measured LDL cholesterol levels
(−0.3%), despite an 8.8% reduction in TG levels and an 8.2% increase
in HDL cholesterol levels. In contrast, at week 24 total PCSK9 levels
increased among alirocumab-treated individuals by +413.3% and free
PCSK9 decreased by −60.6%, reflecting that most circulating PCSK9
was bound to alirocumab. This, in turn, reduced ApoB and non-HDL
cholesterol levels and LDL particle number by approximately one-
third and measured LDL cholesterol by approximately two-fifths,
compared with the more modest reductions in the UC group, and
resulted in a greater proportion (66.9%) of individuals achieving non-
HDL cholesterol <2.59 mmol/L (<100 mg/dL) with alirocumab vs the
addition of UC to statins (17.7%). Taken together, these results dem-
onstrate the significant impact on clearance of atherogenic particles
by targeting PCSK9 for inhibition with alirocumab compared with the
different modes of actions of the UC therapies. Conversely, extracel-
lular PCSK9 inhibition with alirocumab does not appear to substan-
tially affect TG metabolism, although reductions in TG levels with
alirocumab were similar to those observed with fenofibrate.
Based on post hoc data from the ACCORD trial or from meta-
analyses of fibrate trials,16,17 many clinicians add fibrates to statins in
individuals with high TGs or high TGs/low HDL cholesterol. However,
in the present prespecified analyses we demonstrate that the addi-
tion of fenofibrate to statins results in little or no reduction in athero-
genic lipoproteins and hence a trivial reduction in their cholesterol
cargo, despite favourable but clinically modest changes in TG and
HDL cholesterol. These data underscore the importance of therapeu-
tic approaches that increase the clearance of atherogenic lipoproteins
rather than other currently available therapies (apart from statins)
that target either synthesis or lipolysis of TG, but which have little
impact on atherogenic cholesterol levels, as demonstrated by modest
improvements in non-HDL cholesterol goal attainment.
Whilst the present data cannot be used to assess whether
favourable changes in atherogenic particle clearance will translate
into better clinical outcomes in patients with T2DM and atherogenic
dyslipidaemia, it should be noted that UC failed to achieve non-HDL
cholesterol levels <2.59 mmol/L (<100 mg/dL; recommended as a
treatment target for individuals with T2DM in guidelines4,5) for the
majority (82.3%). In contrast, at week 24, only 33.1% of the alirocu-
mab group failed to achieve non-HDL cholesterol levels
<2.59 mmol/L (<100 mg/dL). The findings were consistent with pre-
vious subgroup or post hoc analyses which have reported the effect
of PCSK9 inhibitors according to mixed dyslipidaemia or diabetes
status.18–24
This study was not designed to assess CV outcomes. Post hoc
analyses of alirocumab ODYSSEY trials have suggested that event
reduction continues to very-low levels of LDL cholesterol
(~25–50 mg/dL)25; however, this requires confirmation in the forth-
coming ODYSSEY OUTCOMES study, which includes a prespecified
subgroup analysis in individuals with diabetes mellitus (DM). CV out-
comes data are available for other PCSK9 monoclonal antibodies. In
the FOURIER study, in individuals with CV disease (CVD) with and
without T2DM, evolocumab reduced LDL cholesterol by 56 mg/dL
(~1.4 mmol/L) from baseline with a 20% reduction in major CV
events (CV death, myocardial infarction or stroke).26 Similar results
were observed in individuals with DM and stable ASCVD.11 Among
individuals with higher CV risk (46.1–47.8% with DM) a benefit in
reducing major CV events (non-fatal myocardial infarction, non-fatal
stroke, hospitalization for angina requiring revascularization or CV
death) was shown with bococizumab (hazard ratio 0.79; 95% CI 0.65-
0.97; P = .02).27
Non-HDL cholesterol was chosen as the primary endpoint in this
study after reports that it represents a better risk marker than LDL
cholesterol when TG levels are elevated4; however, we acknowledge
that there is no direct strong evidence from randomized trials that
additional changes in non-HDL cholesterol, on top of LDL cholesterol
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reductions, contribute to further CVD reduction. Moreover, it is diffi-
cult to separate reductions in non-HDL cholesterol, LDL cholesterol,
ApoB and LDL particle number, which are highly correlated. There
are data from meta-analyses suggesting that greater reductions in
non-HDL cholesterol and ApoB are related to further reductions in
CVD,28,29 analogous to well-established data for LDL cholesterol
reduction.7,12,26 The importance of reducing atherogenic particle
number has gained further credence with the large genetic analyses
by Ference et al30 demonstrating that, with add-on therapy, which
affects both the quality and content of atherogenic particles, any CV
benefit is more accurately predicted by particle number (as depicted
by changes in ApoB) rather than by LDL cholesterol. This is sup-
ported by findings from the recent REVEAL trial with the cholesteryl
ester transfer protein inhibitor anacetrapib, in which the observed
clinical risk reduction was considerably less than that anticipated by
the observed reductions in LDL cholesterol.31 A meta-regression
analysis of statin and non-statin therapies by Robinson et al28 sug-
gested that every 10 mg/dL (0.1 g/L) reduction in ApoB would result
in a ~6% proportional reduction in CVD risk. Applying those data to
the present population with a starting ApoB level of ~100 mg/dL
(1 g/L), alirocumab, fenofibrate, omega-3 fatty acids and ezetimibe
would be expected to achieve an absolute reduction of 33.8 mg/dL
(0.3 g/L), 3.8 mg/dL (0.04 g/L), 1.9 mg/dL (0.02 g/L) and 8.8 mg/dL
(0.1 g/L), respectively. Extrapolating from the meta-regression, this
would be expected to translate into 20.3%, 2.3%, 1.1% and 5.3%
reductions in the risk of CVD. Notably, the estimated 20.3% risk
reduction is consistent with the observed results from the FOURIER
study,11 and the estimated 5.3% risk reduction is roughly consistent
with the results of the ezetimibe IMPROVE-IT study.12 Our data also
suggest that, unless there is some benefit of TG-lowering per se on
CVD, as yet unidentified and independent of the modest reductions
in ApoB and LDL particle number, the results of the ongoing out-
comes trials for fibrates and fish oils (PROMINENT: NCT03071692;
STRENGTH: NCT02104817; REDUCE-IT: NCT01492361) are
unlikely to show significant CVD risk reduction. Furthermore, based
on these data, there is no rationale for the routine use of fenofibrate
as add-on to statin therapy if the goal of adding it is to reduce non-
HDL cholesterol or ApoB as a means to reduce CV risk.
Statin use has been associated with an increase in risk of T2DM,
and Mendelian randomization studies have reported an association
between PCSK9 loss-of-function mutations and risk of diabe-
tes30,32,33; however, we did not see any clinically relevant effect of
alirocumab on change in glycaemic variables or in use of antihyper-
glycaemic agents in the present study, supporting previous pooled
analyses and sub-analyses,22,34,35 and the more recent analysis from
the FOURIER study,11,26 which indicated no meaningful effect of
PCSK9 inhibitors on either HbA1c or FPG levels or on rates of new-
onset diabetes. However, larger study populations and longer-term
studies are required to further validate the long-term effects of
PCSK9 inhibition, as use of these therapies is likely to be lifelong.
In this study, alirocumab was generally well tolerated, with com-
parable rates of TEAEs between alirocumab and usual care. No local
injection-site reactions (defined as those deemed to be allergic and
requiring medical consultation) were reported in this study in either
treatment arm.
The rate of persistent anti-drug antibodies observed in the pre-
sent study was similar to the overall rate seen in a pooled analysis of
10 ODYSSEY studies, which demonstrated substantial LDL choles-
terol reductions that were maintained over the course of studies,
regardless of anti-drug antibody status.36
Limitations of the present study include its relatively short dura-
tion and the number of individuals enrolled, which did not allow anal-
ysis of rare adverse events. The awareness of treatment might have
introduced bias by study participants and investigators.37 Safety
reporting could have been influenced as study participants and inves-
tigators would have known what treatment they were receiving. Simi-
larly, treatment adherence to diet and other medication may have
been influenced by the participants' knowledge about treatment.
Simultaneous addition of UC therapies was not included in the proto-
col, although it is acknowledged that this may be recommended in
real-life practice.
In conclusion, among individuals with T2DM and mixed dyslipi-
daemia whose total atherogenic cholesterol burden was inadequately
controlled despite maximally tolerated statin therapy, increasing the
clearance of atherogenic lipoproteins with a PCSK9 inhibitor more
effectively reduced total atherogenic cholesterol levels compared
with the usual lipid-lowering therapeutic approaches currently used.
ACKNOWLEDGMENTS
The authors would like to thank the participants, their families, and
all investigators involved in this study. The following people from the
study sponsors reviewed and provided editorial comments on the
manuscript: Lisa Aurand, Ameen Ghannam, Corinne Hanotin and
Michael Howard (Sanofi), and Carol Hudson, Robert Pordy and
Robert Sanchez (Regeneron Pharmaceuticals, Inc.). The sponsor was
involved in the study design, collection, analysis and interpretation of
data, as well as data checking of information provided in the manu-
script. The authors had unrestricted access to study data, were
responsible for all content and editorial decisions, and received no
honoraria related to the development of this publication.
Conflict of interest
K.K.R. has received: personal fees (data safety monitoring board) from
AbbVie, Inc.; consultant fees/honoraria from Aegerion, Algorithm,
Amgen, AstraZeneca, Boehringer Ingelheim, Cerenis, Eli Lilly and
Company, Ionis Pharmaceuticals, Kowa, Medicines Company, MSD,
Novartis, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Resverlogix,
Sanofi and Takeda; and research grants from Kowa, Pfizer, Inc., and
Regeneron Pharmaceuticals, Inc. L.A.L. has received: personal fees
from Esperion; grants and personal fees from Amgen, AstraZeneca,
Eli Lilly and Company, Merck, Regeneron Pharmaceuticals, Inc. and
Sanofi; and grants from Kowa and the Medicine Company. D.M.-W.
has received speaker's bureau and consultant/advisory board fees
from Amgen, AstraZeneca, Boehringer Ingelheim, MSD (Merck),
Novartis, Novo Nordisk and Sanofi. B.C. has received: research fund-
ing and personal fees from Sanofi and Regeneron Pharmaceuticals,
Inc. during the conduct of the study; research funding from Pfizer,
Inc.; and honoraria from AstraZeneca, Pierre Fabre, Janssen, Eli Lilly
RAY ET AL. 1487
and Company, MSD Merck & Co., Novo Nordisk, Sanofi and Takeda.
H.M.C. has received grants, personal fees and non-financial support
from Sanofi and Regeneron Pharmaceuticals, Inc. during the conduct
of the study; grants, personal fees and non-financial support from Eli
Lilly and Company; grants and other support from Roche Pharmaceu-
ticals; grants from Pfizer, Inc., Boehringer Ingelheim, and AstraZeneca
LP; and other support from Bayer. R.R.H. has received research fund-
ing from AstaMed, Eli Lilly and Company, Hitachi, Lexicon, Novo Nor-
disk and Viacyte and is a consultant for and/or advisory panel
member of Alere, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim,
Bristol-Myers Squibb, Elcelyx, Gilead, Intarcia, Ionis, Janssen/John-
son & Johnson, Merck and Sanofi-Aventis. F.J.T. has received
speaker's bureau and consultant/advisory board fees from AstraZe-
neca, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly
and Company, GlaxoSmithKline, Janssen Pharmaceuticals, Merck
Sharpe & Dohme, Novartis Pharmaceuticals Co., Novo Nordisk,
Sanofi and Regeneron Pharmaceuticals, Inc. C.D., M.B.-B. and A.L. are
employees of and shareholders in Sanofi. R.S. is an employee of and
shareholder in Regeneron Pharmaceuticals, Inc. S.D.P. has received
research funding from AstraZeneca, Boheringer Ingelheim, Novartis
Pharmaceuticals Co. and Merck Sharpe & Dohme; and is a consultant
for or has received honoraria from AstraZeneca, Boehringer Ingel-
heim, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceuti-
cals, Laboratoires Servier, Merck Sharpe & Dohme, Novartis
Pharmaceuticals Co., Novo Nordisk, Sanofi, Servier and Takeda
Pharmaceuticals.
Author contributions
K.K.R., L.A.L., D.M.-W., B.C., H.M.C., R.R.H., F.J.T., M.B.-B., C.D., A.L.,
R.S. and S.D.P. contributed to the study design or concept and the
interpretation of the data, and critically reviewed and edited the man-
uscript. In addition, S.D.P. and F.J.T. were investigators who contrib-
uted to the data acquisition. All authors approved the final version.
ORCID
Kausik K. Ray http://orcid.org/0000-0002-7166-060X
Lawrence A. Leiter http://orcid.org/0000-0002-1040-6229
Robert R. Henry http://orcid.org/0000-0002-4821-0117
Stefano Del Prato http://orcid.org/0000-0002-5388-0270
REFERENCES
1. American Diabetes Association. 9. Cardiovascular disease and risk
management. Diabetes Care. 2017;40:S75-S87.
2. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we?
Diabetologia. 2015;58:886-899.
3. Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes,
pre-diabetes, and cardiovascular diseases developed in collabora-
tion with the EASD: the task force on diabetes, pre-diabetes, and
cardiovascular diseases of the European Society of Cardiology
(ESC) and developed in collaboration with the European Associa-
tion for the Study of Diabetes (EASD). Eur Heart J. 2013;34:
3035-3087.
4. Bays HE, Jones PH, Orringer CE, Brown WV, Jacobson TA. National
lipid association annual summary of clinical lipidology 2016. J Clin Lipi-
dol. 2016;10:S1-43.
5. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines
for the management of dyslipidaemias. Eur Heart J. 2016;37:
2999-3058.
6. Ginsberg HN. REVIEW: efficacy and mechanisms of action of statins
in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab.
2006;91:383-392.
7. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more
intensive lowering of LDL cholesterol: a meta-analysis of data from
170,000 participants in 26 randomised trials. Lancet. 2010;376:
1670-1681.
8. Tremblay AJ, Lamarche B, Cohn JS, Hogue JC, Couture P. Effect of
ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men
with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol.
2006;26:1101-1106.
9. Reyes-Soffer G, Pavlyha M, Ngai C, et al. Effects of PCSK9 inhibition
with alirocumab on lipoprotein metabolism in healthy humans. Circu-
lation. 2017;135:352-362.
10. Watts GF, Chan DC, Dent R, et al. Factorial effects of evolocumab
and atorvastatin on lipoprotein metabolism. Circulation. 2017;135:
338-351.
11. Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and
efficacy of the PCSK9 inhibitor evolocumab in patients with and
without diabetes and the effect of evolocumab on glycaemia and risk
of new-onset diabetes: a prespecified analysis of the FOURIER ran-
domised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941-950.
12. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investiga-
tors; Ezetimibe added to statin therapy after acute coronary syn-
dromes. N Engl J Med. 2015;372:2387-2397.
13. Müller-Wieland D, Leiter LA, Cariou B, et al. Design and rationale of
the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and
safety of alirocumab in individuals with type 2 diabetes and mixed
dyslipidaemia at high cardiovascular risk. Cardiovasc Diabetol. 2017;
16:70.
14. Rey J, Poitiers F, Paehler T, et al. Relationship between low-density
lipoprotein cholesterol, free proprotein convertase subtilisin/kexin
type 9, and alirocumab levels after different lipid-lowering strategies.
J Am Heart Assoc. 2016;5:e003323.
15. Costet P, Hoffmann MM, Cariou B, Guyomarc'h Delasalle B,
Konrad T, Winkler K. Plasma PCSK9 is increased by fenofibrate and
atorvastatin in a non-additive fashion in diabetic patients. Atheroscle-
rosis. 2010;212:246-251.
16. ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of com-
bination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;
362:1563-1574.
17. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type
2 diabetes. N Engl J Med. 2010;363:692-694. author reply 694–695.
18. Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM
Investigators; Efficacy and safety of alirocumab in reducing lipids and
cardiovascular events. N Engl J Med. 2015;372:1489-1499.
19. Taskinen MR, Del Prato S, Bujas-Bobanovic M, Louie MJ,
Lorenzato C, Colhoun HM. Alirocumab in individuals with diabetes
and mixed dyslipidemia: pooled analyses of five phase 3 trials: pre-
sented at the International Diabetes Federation World Congress
2015, Abstract 0272-PD.2015. http://conference.idf.org/IDF2015/
CM.NET.WebUI/CM.NET.WEBUI.SCPR2/SCPRfunctiondetail.aspx?c
onfID=05000000-0000-0000-0000-000000000003&sesID=050000
00-0000-0000-0000-000000001704&absID=07000000-0000-0000
-0000-000000011066. Accessed July 27, 2017.
20. Ginsberg HN, Farnier M, Robinson JG, et al. Efficacy and safety of
alirocumab: pooled analyses of 1048 individuals with diabetes melli-
tus from five placebo-controlled phase 3 studies of at least 52 weeks
duration. Circulation. 2015;132:A17070.
21. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II:
78 week results with alirocumab treatment in 735 patients with hetero-
zygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996-3003.
22. Leiter LA, Zamorano JL, Bujas-Bobanovic M, et al. Lipid-lowering effi-
cacy and safety of alirocumab in patients with or without diabetes: a
sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017;19:
989-996.
23. Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of the
PCSK9 inhibitor evolocumab (AMG 145) in patients with type
1488 RAY ET AL.
2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes
Endocrinol. 2016;4:403-410.
24. Rosenson RS, Jacobson TA, Preiss D, et al. Efficacy and safety of the
PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia.
Cardiovasc Drugs Ther. 2016;30:305-313.
25. Ray KK, Ginsberg HN, Davidson MH, et al. Reductions in atherogenic
lipids and major cardiovascular events: a pooled analysis of 10 ODYS-
SEY trials comparing alirocumab with control. Circulation. 2016;134:
1931-1943.
26. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical
outcomes in patients with cardiovascular disease. N Engl J Med. 2017;
376:1713-1722.
27. Ridker PM, Revkin J, Amarenco P, et al. SPIRE Cardiovascular Out-
come Investigators; Cardiovascular efficacy and safety of bococizu-
mab in high-risk patients. N Engl J Med. 2017;376:1527-1539.
28. Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of
effectiveness of lowering apolipoprotein B versus low-density lipo-
protein cholesterol and nonhigh-density lipoprotein cholesterol for
cardiovascular risk reduction in randomized trials. Am J Cardiol. 2012;
110:1468-1476.
29. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the rela-
tionship between non-high-density lipoprotein cholesterol reduction
and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316-322.
30. Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and
HMGCR and risk of cardiovascular disease and diabetes. N Engl J
Med. 2016;375:2144-2153.
31. Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in
patients with atherosclerotic vascular disease. N Engl J Med. 2017;
377:1217-1227.
32. Lotta LA, Sharp SJ, Burgess S, et al. Association between
low-density lipoprotein cholesterol-lowering genetic variants and
risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316:
1383-1391.
33. Schmidt AF, Swerdlow DI, Holmes MV, et al. LifeLines Cohort study
group; UCLEB consortium; PCSK9 genetic variants and risk of type
2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocri-
nol. 2017;5:97-105.
34. Blom DJ, Koren MJ, Roth E, et al. Evaluation of the efficacy, safety
and glycaemic effects of evolocumab (AMG 145) in hypercholestero-
laemic patients stratified by glycaemic status and metabolic syn-
drome. Diabetes Obes Metab. 2017;19:98-107.
35. Colhoun HM, Ginsberg HN, Robinson JG, et al. No effect of PCSK9
inhibitor alirocumab on the incidence of diabetes in a pooled analysis
from 10 ODYSSEY phase 3 studies. Eur Heart J. 2016;37:2981-2989.
36. Roth EM, Goldberg AC, Catapano AL, et al. Antidrug antibodies in
patients treated with alirocumab. N Engl J Med. 2017;376:1589-1590.
37. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation
and elaboration: guidance for protocols of clinical trials. BMJ. 2013;
346:e7586.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the sup-
porting information tab for this article.
How to cite this article: Ray KK, Leiter LA, Müller-
Wieland D, et al. Alirocumab vs usual lipid-lowering care as
add-on to statin therapy in individuals with type 2 diabetes
and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA
randomized trial. Diabetes Obes Metab. 2018;20:1479–1489.
https://doi.org/10.1111/dom.13257
RAY ET AL. 1489
